The safety of vedolizumab for ulcerative colitis and Crohn's disease

Jean Frédéric Colombel, Bruce E. Sands, Paul Rutgeerts, William Sandborn, Silvio Danese, Geert D'Haens, Remo Panaccione, Edward V. Loftus, Serap Sankoh, Irving Fox, Asit Parikh, Catherine Milch, Brihad Abhyankar, Brian G. Feagan

Research output: Contribution to journalArticlepeer-review

Abstract

Objective Vedolizumab is a gut-selective antibody to a4ß7 integrin for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). We report an integrated summary of the safety of vedolizumab. Design Safety data (May 2009-June 2013) from six trials of vedolizumab were integrated. Adverse events were evaluated in patients who received =1 dose of vedolizumab or placebo and were reported as exposureadjusted incidence rates as the number of patients experiencing the event per 100 person-years (PYs) of exposure. Predictors of serious infection were assessed using a Cox proportional hazards model. Results In total, 2830 patients had 4811 PYs of vedolizumab exposure (median exposure range, 1- 1977 days). No increased risk of any infection or serious infection was associated with vedolizumab exposure. Serious clostridial infections, sepsis and tuberculosis were reported infrequently (=0.6% of patients). No cases of progressive multifocal leucoencephalopathy were observed. Independent risk factors for serious infection in UC were prior failure of a tumour necrosis factor a antagonist (HR, 1.99; 95% CIs 1.16 to 3.42; p=0.0122) and narcotic analgesic use (HR, 2.68; 95% CI 1.57 to 4.58; p=0.0003), and in CD were younger age (HR, 0.97; 95% CI 0.95 to 0.98; p

Original languageEnglish
JournalGut
DOIs
Publication statusAccepted/In press - Feb 18 2016

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'The safety of vedolizumab for ulcerative colitis and Crohn's disease'. Together they form a unique fingerprint.

Cite this